小剂量重组织型纤溶酶原激活剂与尿激酶、重组链激酶溶栓治疗急性心肌梗死的临床对比分析
小剂量重组织型纤溶酶原激活剂；尿激酶；重组链激酶；急性心肌梗死,,],小剂量重组织型纤溶酶原激活剂；尿激酶；重组链激酶；急性心肌梗死,1临床资料,2结果,3讨论,[参考文献]
[摘要] 目的 观察小剂量重组织型纤溶酶原激活剂(rt-PA)、尿激酶(UK)和重组链激酶(r-SK)治疗急性心肌梗死的疗效和安全性。方法 114例急性心肌梗死患者随机分为rt-PA组38例，UK组37例，r-SK组39例。分别应用纤溶酶原激活剂50 mg、尿激酶150万u、链激酶150万u静脉输入。结果 rt-PA组、UK组、r-SK组临床血管再通率分别为84.21%、51.35%、69.23%，三者之间疗效比较P<0.05。3组溶栓后不良反应、5周病死率比较P>0.05，差异无显著性。结论 rt-PA治疗急性心肌梗死的疗效明显优于UK和r-SK，而r-SK的疗效优于UK。溶栓后不良反应、5周病死率比较差异无显著性。[关键词] 小剂量重组织型纤溶酶原激活剂；尿激酶；重组链激酶；急性心肌梗死
Clinical comparison and analysis of low dose recombinant tissue-type plasminogen activator,urokinase and recombinant streptokinase in embolism therapy for acute myocardial infarction
ZHAO Guozhong,LIN Wei,FENG Xiaolan.Hospital of Scientific City，Mianyang 621900,China
[Abstract] Objective To observe the therapeutic effect and safety of low dose recombinant tissue-type plasminogen activator(rt-PA),urokinase(UK) and recombinant streptokinase(r-SK) in embolism therapy for acute myocardial infarction. Methods One hundred and fourteen cases were randomly divided into rt-PA group(38 cases),urokinase group(37 cases) and recombinant streptokinase group(39 cases),which were treated with 50 mg rt-PA,1.5Mu UK and1.5Mu r-SK intravenous infusion respectively. Results The clinical reperfusion rates in rt-PA,UK and r-SK was 84.21%,51.35% and 69.23%(P<0.05).Among the three groups,there was no significant difference in side effect and 5-week mortality(P>0.05).Conclusion Low dose rt-PA was effective for acute myocardial infarction than UK and r-SK,and the therapeutic effect of r-SK was better than UK.There was no significant difference in side effect and 5-week mortality after thrombolytic therapy. ......
您现在查看是摘要页，全文长 8436 字符。